Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
(Summary) (Chart)
(Summary) (Chart)
| 19 August 2018 Price $37.56 1yr Target $48.67 Analysts 3 Dividend $0.00 Payout Ratio --- 1yr Cap Gain 29.57% Yield 0.00% 1yr Tot Return 29.57% | EPS (ttm) $0.05 EPS next yr $0.12 Forward P/E 302.90 EPS next 5yr 74.90% 1yr Price Support $8.98 Market Cap $1.24 Bil Revenues $217.00 Mil Earnings $1.70 Mil Profit Margin 0.78% | P/E 766.53 PEG 10.23 Beta 2.48 Quick Ratio 4.00 Current Ratio 4.50 Debt/Equity 0.17 ROA -1.80% ROE -2.80% |
 Daily Chart |  Weekly Chart |
My Strategy
An investment in these shares is really a balancing act between buying something that's extremely overpriced versus something that's growing at a phenomenal rate. Add in a rather high beta and it makes sense to wait for a buying opportunity. That may mean waiting for a pullback to the 200 dma which is currently below $30 per share. But waiting for a fall that large may never happen. Options is another strategy but at this price you;d have to sell puts with a strike price so far away from the current price that the premium probably isn't worth the effort. Another option would be to sell puts farther out but then the exposure is too long. So this only works for me if the actually shares drop. I'll put this on my watch list and see what happens.
An investment in these shares is really a balancing act between buying something that's extremely overpriced versus something that's growing at a phenomenal rate. Add in a rather high beta and it makes sense to wait for a buying opportunity. That may mean waiting for a pullback to the 200 dma which is currently below $30 per share. But waiting for a fall that large may never happen. Options is another strategy but at this price you;d have to sell puts with a strike price so far away from the current price that the premium probably isn't worth the effort. Another option would be to sell puts farther out but then the exposure is too long. So this only works for me if the actually shares drop. I'll put this on my watch list and see what happens.
Print 
PDF
RSS Feed
